Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 208

1.

HILIC/ESI-MS determination of gangliosides and other polar lipid classes in renal cell carcinoma and surrounding normal tissues.

Hájek R, Lísa M, Khalikova M, Jirásko R, Cífková E, Študent V Jr, Vrána D, Opálka L, Vávrová K, Matzenauer M, Melichar B, Holčapek M.

Anal Bioanal Chem. 2018 Oct;410(25):6585-6594. doi: 10.1007/s00216-018-1263-8. Epub 2018 Jul 28.

PMID:
30054694
2.

Hemodiafiltration and plasma levels of axitinib in a patient with metastatic renal clear cell carcinoma.

Kopecky J, Ticha A, Janeckova H, Bohuslav M.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018 May 15. doi: 10.5507/bp.2018.021. [Epub ahead of print]

PMID:
29765173
3.

Simulations of centriole of polarized centrosome as a monopole antenna in immune and viral synapses.

Dvorak J, Melichar B, Filipova A, Grimova J, Grimova N, Rozsypalova A, Buka D, Voboril R, Zapletal R, Buchler T, Richter I, Buka D.

J BUON. 2018 Mar-Apr;23(2):514-521.

PMID:
29745101
4.

Lenvatinib for the treatment of kidney cancer.

Študentová H, Vitásková D, Melichar B.

Expert Rev Anticancer Ther. 2018 Jun;18(6):511-518. doi: 10.1080/14737140.2018.1470506. Epub 2018 May 8.

PMID:
29737893
5.

Immunotherapy in mucosal melanoma: a case report and review of the literature.

Studentova H, Kalabova H, Koranda P, Chytilova K, Kucerova L, Melichar B, Vrana D.

Oncotarget. 2018 Apr 3;9(25):17971-17977. doi: 10.18632/oncotarget.24727. eCollection 2018 Apr 3.

6.

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators.

N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.

PMID:
29562145
7.

ABC Transporters and Their Role in the Neoadjuvant Treatment of Esophageal Cancer.

Vrana D, Hlavac V, Brynychova V, Vaclavikova R, Neoral C, Vrba J, Aujesky R, Matzenauer M, Melichar B, Soucek P.

Int J Mol Sci. 2018 Mar 15;19(3). pii: E868. doi: 10.3390/ijms19030868. Review.

8.

[Current Status of Checkpoint Inhibitors in the Treatment of Esophageal and Gastric Tumors - Overview of Studies].

Vrána D, Matzenauer M, Melichar B.

Klin Onkol. 2017 Winter;31(1):35-39. doi: 10.14735/amko201835. Czech.

PMID:
29488776
9.

Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

Maio M, Lewis K, Demidov L, Mandalà M, Bondarenko I, Ascierto PA, Herbert C, Mackiewicz A, Rutkowski P, Guminski A, Goodman GR, Simmons B, Ye C, Yan Y, Schadendorf D; BRIM8 Investigators.

Lancet Oncol. 2018 Apr;19(4):510-520. doi: 10.1016/S1470-2045(18)30106-2. Epub 2018 Feb 21. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184.

PMID:
29477665
10.

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.

Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ; SPARTAN Investigators.

N Engl J Med. 2018 Apr 12;378(15):1408-1418. doi: 10.1056/NEJMoa1715546. Epub 2018 Feb 8.

PMID:
29420164
11.

Association of the combined parameters including the frequency of primary cilia, CD8+ tumor infiltrating lymphocytes and PD-1 expression with the outcome in intestinal cancer.

Dvorak J, Hadzi Nikolov D, Dusek L, Filipova A, Richter I, Buka D, Ryska A, Mokry J, Filip S, Melichar B, Buchler T, Abrahamova J.

J BUON. 2017 Nov-Dec;22(6):1477-1487.

PMID:
29332341
12.

Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients.

Poprach A, Fiala O, Chloupkova R, Melichar B, Lakomy R, Petrakova K, Zemanova M, Kopeckova K, Slaby O, Studentova H, Kopecký J, Kiss I, Finek J, Dusek L, Buchler T.

Anticancer Res. 2018 Jan;38(1):449-456.

PMID:
29277808
13.

Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry.

Lakomy R, Poprach A, Bortlicek Z, Melichar B, Chloupkova R, Vyzula R, Zemanova M, Kopeckova K, Svoboda M, Slaby O, Kiss I, Studentova H, Juracek J, Fiala O, Kopecky J, Finek J, Dusek L, Hejduk K, Buchler T.

BMC Cancer. 2017 Dec 21;17(1):880. doi: 10.1186/s12885-017-3901-5.

14.

Scientific publishing in the "predatory" era.

Lippi G, Gillery P, Lackner KJ, Melichar B, Payne DA, Schlattmann P, Tate JR, Plebani M.

Clin Chem Lab Med. 2018 Apr 25;56(5):683-684. doi: 10.1515/cclm-2017-1079. No abstract available.

PMID:
29252192
15.

Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor.

Niu H, Shin H, Gao F, Zhang J, Bahamon B, Danaee H, Melichar B, Schilder RJ, Coleman RL, Falchook G, Adenis A, Behbakht K, DeMichele A, Dees EC, Perez K, Matulonis U, Sawrycki P, Huebner D, Ecsedy J.

EBioMedicine. 2017 Nov;25:50-57. doi: 10.1016/j.ebiom.2017.10.015. Epub 2017 Oct 16.

16.

Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome.

Lemstrova R, Brynychova V, Hughes DJ, Hlavac V, Dvorak P, Doherty JE, Murray HA, Crockard M, Oliverius M, Hlavsa J, Honsova E, Mazanec J, Kala Z, Lovecek M, Havlik R, Ehrmann J, Strouhal O, Soucek P, Melichar B, Mohelnikova-Duchonova B.

Oncol Lett. 2017 Nov;14(5):5980-5988. doi: 10.3892/ol.2017.6946. Epub 2017 Sep 14.

17.

Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of the literature.

Lovecek M, Skalicky P, Chudacek J, Szkorupa M, Svebisova H, Lemstrova R, Ehrmann J, Melichar B, Yogeswara T, Klos D, Vrba R, Havlik R, Mohelnikova-Duchonova B.

World J Gastroenterol. 2017 Sep 21;23(35):6420-6428. doi: 10.3748/wjg.v23.i35.6420. Review.

18.

Tumor microenvironment and systemic disease: a dual target in medical oncology (also in the case of biomarkers).

Melichar B.

Clin Chem Lab Med. 2017 Oct 26;55(12):1813-1816. doi: 10.1515/cclm-2017-0797. No abstract available.

19.

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.

Motzer RJ, Haas NB, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, Lee JL, Melichar B, Rini BI, Choueiri TK, Zemanova M, Wood LA, Reaume MN, Stenzl A, Chowdhury S, Lim HY, McDermott R, Michael A, Bao W, Carrasco-Alfonso MJ, Aimone P, Voi M, Doehn C, Russo P, Sternberg CN; PROTECT investigators.

J Clin Oncol. 2017 Dec 10;35(35):3916-3923. doi: 10.1200/JCO.2017.73.5324. Epub 2017 Sep 13.

20.

RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer.

Baselga J, Zamagni C, Gómez P, Bermejo B, Nagai SE, Melichar B, Chan A, Mángel L, Bergh J, Costa F, Gómez HL, Gradishar WJ, Hudis CA, Rapoport BL, Roché H, Maeda P, Huang L, Meinhardt G, Zhang J, Schwartzberg LS.

Clin Breast Cancer. 2017 Dec;17(8):585-594.e4. doi: 10.1016/j.clbc.2017.05.006. Epub 2017 May 22.

PMID:
28830796

Supplemental Content

Loading ...
Support Center